Cite
83P Evaluation of concordance between PD-L1 immunohistochemistry 28-8 and 22C3 pharmDx assays in metastatic urothelial carcinoma (mUC) in PIVOT-10.
MLA
Siefker-Radtke, A. O., et al. “83P Evaluation of Concordance between PD-L1 Immunohistochemistry 28-8 and 22C3 PharmDx Assays in Metastatic Urothelial Carcinoma (MUC) in PIVOT-10.” Annals of Oncology, vol. 32, Sept. 2021, pp. S392–93. EBSCOhost, https://doi.org/10.1016/j.annonc.2021.08.363.
APA
Siefker-Radtke, A. O., Hoch, U., Loriot, Y., Balar, A. V., Bilen, M. A., Tannir, N. M., Cho, D. C., Choudhury, A., Chien, D., Yu, D., Currie, S. L., Novotny, J., Santiago, L., Tagliaferri, M. A., Zalevsky, J., & Huddart, R. A. (2021). 83P Evaluation of concordance between PD-L1 immunohistochemistry 28-8 and 22C3 pharmDx assays in metastatic urothelial carcinoma (mUC) in PIVOT-10. Annals of Oncology, 32, S392–S393. https://doi.org/10.1016/j.annonc.2021.08.363
Chicago
Siefker-Radtke, A.O., U. Hoch, Y. Loriot, A.V. Balar, M.A. Bilen, N.M. Tannir, D.C. Cho, et al. 2021. “83P Evaluation of Concordance between PD-L1 Immunohistochemistry 28-8 and 22C3 PharmDx Assays in Metastatic Urothelial Carcinoma (MUC) in PIVOT-10.” Annals of Oncology 32 (September): S392–93. doi:10.1016/j.annonc.2021.08.363.